Metropolitan Life Insurance Company (MetLife)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,384
| Closed | -$44.2K | – | 2416 |
|
|
2023
Q3 | $44.2K | Buy |
2,384
+1,086
| +84% | +$12.3K | ﹤0.01% | 1477 |
|
|
2023
Q2 | $14.4K | Hold |
1,298
| – | – | ﹤0.01% | 2105 |
|
|
2023
Q1 | $17.4K | Sell |
1,298
-372
| -22% | -$6.44K | ﹤0.01% | 1956 |
|
|
2022
Q4 | $20.7K | Hold |
1,670
| – | – | ﹤0.01% | 1993 |
|
|
2022
Q3 | $23.3K | Hold |
1,670
| – | – | ﹤0.01% | 1955 |
|
|
2022
Q2 | $23.1K | Hold |
1,670
| – | – | ﹤0.01% | 1979 |
|
|
2022
Q1 | $27.2K | Sell |
1,670
-5,261
| -76% | -$82.4K | ﹤0.01% | 1946 |
|
|
2021
Q4 | $113K | Sell |
6,931
-984
| -12% | -$16.6K | ﹤0.01% | 2407 |
|
|
2021
Q3 | $118K | Hold |
7,915
| – | – | ﹤0.01% | 2434 |
|
|
2021
Q2 | $158K | Hold |
7,915
| – | – | ﹤0.01% | 2320 |
|
|
2021
Q1 | $183K | Hold |
7,915
| – | – | ﹤0.01% | 2081 |
|
|
2020
Q4 | $196K | Hold |
7,915
| – | – | ﹤0.01% | 1954 |
|
|
2020
Q3 | $328K | Hold |
7,915
| – | – | 0.01% | 1488 |
|
|
2020
Q2 | $379K | Buy |
7,915
+433
| +6% | +$33.4K | 0.01% | 1403 |
|
|
2020
Q1 | $471K | Sell |
7,482
-448
| -6% | -$40.3K | 0.01% | 1075 |
|
|
2019
Q4 | $983K | Sell |
7,930
-183
| -2% | -$16.4K | 0.02% | 910 |
|
|
2019
Q3 | $538K | Buy |
8,113
+744
| +10% | +$50K | 0.01% | 1240 |
|
|
2019
Q2 | $586K | Buy |
7,369
+199
| +3% | +$17.8K | 0.01% | 1208 |
|
|
2019
Q1 | $802K | Hold |
7,170
| – | – | 0.01% | 1008 |
|
|
2018
Q4 | $723K | Hold |
7,170
| – | – | 0.01% | 982 |
|
|
2018
Q3 | $906K | Hold |
7,170
| – | – | 0.02% | 988 |
|
|
2018
Q2 | $602K | Buy |
7,170
+5,834
| +437% | +$427K | 0.01% | 1189 |
|
|
2018
Q1 | $82.2K | Buy |
1,336
+1
| +0.1% | +$60 | ﹤0.01% | 2375 |
|
|
2017
Q4 | $78K | Sell |
1,335
-15
| -1% | -$946 | ﹤0.01% | 2414 |
|
|
2017
Q3 | $78K | Buy |
1,350
+69
| +5% | +$7.43K | ﹤0.01% | 2430 |
|
|
2017
Q2 | $155K | Buy |
1,281
+155
| +14% | +$18K | ﹤0.01% | 2467 |
|
|
2017
Q1 | $127K | Hold |
1,126
| – | – | ﹤0.01% | 2418 |
|
|
2016
Q4 | $122K | Sell |
1,126
-52
| -4% | -$6.2K | ﹤0.01% | 2511 |
|
|
2016
Q3 | $194K | Sell |
1,178
-56
| -5% | -$8.83K | ﹤0.01% | 2353 |
|
|
2016
Q2 | $176K | Buy |
1,234
+38
| +3% | +$5.54K | ﹤0.01% | 2408 |
|
|
2016
Q1 | $154K | Hold |
1,196
| – | – | ﹤0.01% | 2326 |
|
|
2015
Q4 | $179K | Buy |
1,196
+32
| +3% | +$5.42K | ﹤0.01% | 2331 |
|
|
2015
Q3 | $193K | Hold |
1,164
| – | – | ﹤0.01% | 2308 |
|
|
2015
Q2 | $281K | Buy |
1,164
+223
| +24% | +$59.4K | ﹤0.01% | 2163 |
|
|
2015
Q1 | $265K | Buy |
941
+62
| +7% | +$13.4K | ﹤0.01% | 1905 |
|
|
2014
Q4 | $137K | Buy |
879
+23
| +3% | +$4.25K | ﹤0.01% | 2559 |
|
|
2014
Q3 | $203K | Sell |
856
-6
| -0.7% | -$1.53K | ﹤0.01% | 2355 |
|
|
2014
Q2 | $204K | Sell |
862
-4,766
| -85% | -$1.26M | ﹤0.01% | 2497 |
|
|
2014
Q1 | $1.86M | Sell |
5,628
-24
| -0.4% | -$8.1K | 0.01% | 1021 |
|
|
2013
Q4 | $386K | Hold |
5,652
| – | – | ﹤0.01% | 1994 |
|
|
2013
Q3 | $390K | Hold |
5,652
| – | – | ﹤0.01% | 1934 |
|
|
2013
Q2 | $253K | Buy |
+5,652
| New | +$193K | ﹤0.01% | 2176 |
|
Metropolitan Life Insurance Company (MetLife)'s ICPT Position: Q4 2023 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 2,384 shares — an estimated $44.2K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $1.86M in Q1 2014. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 2,384 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $44.2K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Intercept Pharmaceuticals, Inc. position peaked at $1.86M in Q1 2014.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.